Expert Review of Anticancer Therapy最新文献_第3页

Interventions to reduce the risk of side-effects of cancer treatments in childhood. 降低儿童癌症治疗副作用风险的干预措施。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-10-09 DOI: 10.1080/14737140.2024.2411255

Bob Phillips, Jess Morgan, Ruth Walker, Claudia Heggie, Salah Ali

{"title":"Interventions to reduce the risk of side-effects of cancer treatments in childhood.","authors":"Bob Phillips, Jess Morgan, Ruth Walker, Claudia Heggie, Salah Ali","doi":"10.1080/14737140.2024.2411255","DOIUrl":"10.1080/14737140.2024.2411255","url":null,"abstract":"Introduction: Childhood cancers as a group affect around 1 in 500 children but each individual diagnosis is a rare disease. While research largely focuses on improving cure rates, the management of side effects of treatment are high priority for clinicians, families and children and young people.Areas covered: The prevention and efficient management of infectious complications, oral mucositis, nausea and vomiting and graft-vs-host disease illustrated with examples of implementation research, translation of engineering to care, advances in statistical methodologies, and traditional bench-to-patient development. The reviews draw from existing systematic reviews and well conducted clinical practice guidelines.Expert opinion: The four areas are driven from patient and family priorities. Some of the problems outlined are ready for proven interventions, others require us to develop new technologies. Advancement needs us to make the best use of new methods of applied health research and clinical trial methodologies. Some of the greatest challenges may be those we're not fully aware of, as new therapies move from their use in adult oncological practice into children. This will need us to continue our collaborative, multi-professional, multi-disciplinary and eclectic approach.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1117-1129"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142389163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions. 骨髓增生异常综合征/肿瘤（MDS）的靶向疗法：当前形势与未来方向。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-10-17 DOI: 10.1080/14737140.2024.2414071

Aram Bidikian, Jan P Bewersdorf, Rory M Shallis, Ted M Getz, Jessica M Stempel, Tariq Kewan, Maximilian Stahl, Amer M Zeidan

{"title":"Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions.","authors":"Aram Bidikian, Jan P Bewersdorf, Rory M Shallis, Ted M Getz, Jessica M Stempel, Tariq Kewan, Maximilian Stahl, Amer M Zeidan","doi":"10.1080/14737140.2024.2414071","DOIUrl":"10.1080/14737140.2024.2414071","url":null,"abstract":"Introduction: Myelodysplastic syndromes/neoplasms (MDS) are a heterogeneous group of hematologic malignancies that are stratified into high-risk (HR-MDS) and low-risk (LR-MDS) categories. Until recently, LR-MDS has been typically managed by supportive measures and erythropoiesis-stimulating agents (ESAs); whereas management of HR-MDS typically included hypomethylating agents and allogeneic hematopoietic stem cell transplant. However, the limited rates and durations of response observed with these interventions prompted the search for targeted therapies to improve the outcomes among patients with MDS.Areas covered: Here, we review the current landscape of targeted therapies in MDS. These include pyruvate kinase and hypoxia-inducible factor (HIF) activators; TGF-beta, telomerase, BCL2 and isocitrate dehydrogenase (IDH) inhibitors; as well as novel approaches targeting inflammation, pyroptosis, immune evasion, and RNA splicing machinery.Expert opinion: This review highlights the progress and challenges in MDS treatment. Despite some promising results, many therapies remain in early development or have faced setbacks, emphasizing the need for a more comprehensive understanding of the disease's pathobiology. Continued research into targeted therapies, homogenous clinical trial designs, as well as increased incorporation of molecular prognostic tools and artificial intelligence into trial design are essential for developing effective treatments for MDS and improving patient outcomes.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1131-1146"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Future investigative directions for novel therapeutic targets in head and neck cancer. 头颈癌新型治疗靶点的未来研究方向。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-10-16 DOI: 10.1080/14737140.2024.2417038

Jacqueline P Nguyen, Liam C Woerner, Daniel E Johnson, Jennifer R Grandis

引用次数: 0

Treatment of skin cancers in solid organ transplant recipients: current status and future perspectives. 实体器官移植受者皮肤癌的治疗：现状与未来展望。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-09-24 DOI: 10.1080/14737140.2024.2408280

Emilie Ducroux, Jean Kanitakis

引用次数: 0

Infrared radiation for cancer hyperthermia: the light to brighten up oncology. 用于癌症热疗的红外线辐射：照亮肿瘤学的明灯。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-10-18 DOI: 10.1080/14737140.2024.2416063

Mengna Ye, Dashan Yin, Yufei Wu, Hua Miao, Zhibing Wu, Pengyuan Liu

{"title":"Infrared radiation for cancer hyperthermia: the light to brighten up oncology.","authors":"Mengna Ye, Dashan Yin, Yufei Wu, Hua Miao, Zhibing Wu, Pengyuan Liu","doi":"10.1080/14737140.2024.2416063","DOIUrl":"10.1080/14737140.2024.2416063","url":null,"abstract":"Introduction: Cancer constitutes the greatest public health threat to humans, as its incidence and mortality rates continue to increase worldwide. With the development of medical physics, more practitioners focus on the direct and indirect anti-tumor effects of physical factors. Infrared radiation (INR) is currently the most rapidly developing physical therapy method for tumors and has become a favored target for many oncologists and researchers owing to its advantages of high efficiency, low toxicity, and strong feasibility.Areas covered: This work provides a comprehensive collection of the latest information on INR anti-tumor research, drawing from public medical databases (PubMed, Web of Science, Embase, and Clinical Trials) from the last 10 years (2014 to 2024), and encompassing both basic and clinical research in oncology and physics. This article reviews the application of INR in tumor hyperthermia, summarizes and analyzes the practical value of INR for tumor treatment, and discusses future development trends to provide valuable assistance for the subsequent development of oncology.Expert opinion: Currently, INR has continuously accumulated excellent data in the field of tumor hyperthermia, bringing practical survival benefits to patients with cancer, and playing an important role in basic and clinical cancer research.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1147-1160"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic accuracy of magnetic resonance diffusion tensor imaging in distinguishing pseudoprogression from glioma recurrence: a systematic review and meta-analysis. 磁共振弥散张量成像在区分假性进展和胶质瘤复发方面的诊断准确性：系统回顾和荟萃分析。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-10-14 DOI: 10.1080/14737140.2024.2415404

Xiaoyi Wu, Mai Zhang, Quan Jiang, Mingxi Li, Yuankui Wu

{"title":"Diagnostic accuracy of magnetic resonance diffusion tensor imaging in distinguishing pseudoprogression from glioma recurrence: a systematic review and meta-analysis.","authors":"Xiaoyi Wu, Mai Zhang, Quan Jiang, Mingxi Li, Yuankui Wu","doi":"10.1080/14737140.2024.2415404","DOIUrl":"10.1080/14737140.2024.2415404","url":null,"abstract":"Purpose: To evaluate the diagnostic accuracy of diffusion tensor imaging (DTI)-derived metrics mean diffusivity (MD) and fractional anisotropy (FA) in differentiating glioma recurrence from pseudoprogression.Methods: The Cochrane Library, Scopus, PubMed, and the Web of Science were systematically searched. Study selection and data extraction were done by two investigators independently. The quality assessment of diagnostic accuracy studies was applied to evaluate the quality of the included studies. Combined sensitivity (SEN) and specificity (SPE) and the area under the summary receiver operating characteristic curve (SROC) with the 95% confidence interval (CI) were calculated.Results: Seven high-quality studies involving 246 patients were included. Quantitative synthesis of studies showed that the pooled SEN and SPE for MD were 0.81 (95% CI 0.70-0.88) and 0.82 (95% CI 0.70-0.90), respectively, and the value of the area under the SROC curve was 0.88 (95% CI 0.85-0.91). The pooled SEN and SPE for FA were 0.74 (95% CI 0.65-0.82) and 0.79 (95% CI 0.66-0.88), respectively, and the value of the area under the SROC curve was 0.84 (95% CI 0.80-0.87).Conclusions: This meta-analysis showed that both MD and FA have a high diagnostic accuracy in differentiating glioma recurrence from pseudoprogression.Registration: PROSPERO protocol: CRD42024501146.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1177-1185"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer. 曲妥珠单抗-德鲁司坦治疗晚期 HER2 低乳腺癌患者的疗效。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2023-09-12 DOI: 10.1080/14737140.2023.2171993

Ilana Schlam, Sara M Tolaney, Paolo Tarantino

{"title":"The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer.","authors":"Ilana Schlam, Sara M Tolaney, Paolo Tarantino","doi":"10.1080/14737140.2023.2171993","DOIUrl":"10.1080/14737140.2023.2171993","url":null,"abstract":"Introduction: Until recently, the available human receptor epidermal growth factor 2 (HER2) targeted agents were ineffective for treating patients with HER2-low expressing breast cancer (defined as immunohistochemical expression of 1+ or 2+ without amplification). The development of novel and potent HER2-directed antibody-drug conjugates, affective at treating HER2-low expressing breast cancers, have changed the way we think about HER2-low expression and expanded the treatment options for many patients with advanced disease.Areas covered: In this review, we summarize the current management of HER2-low breast cancer and commonly encountered challenges such as treatment sequencing and toxicity management.Expert opinion: trastuzumab deruxtecan (T-DXd) is a treatment option for patients with advanced, HER2-low breast cancer, irrespective of the hormone receptor status. The current optimal place in treatment algorithms is after the first line of chemotherapy, both in HR-positive and triple-negative breast cancer; however, other agents are available in this setting and risks and benefits for each should be considered in shared decision making. Up to 10-15% of patients receiving T-DXd develop interstitial lung disease. Patient and clinician education are key to safely implement T-DXd in clinical practice.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1059-1066"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10208624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The diagnostic value of CYFRA 21-1 in oral squamous cell carcinoma: a meta-analysis. CYFRA 21-1 在口腔鳞状细胞癌中的诊断价值：一项荟萃分析。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-11-01 Epub Date: 2024-09-23 DOI: 10.1080/14737140.2024.2405225

Yuting Liang, Zhenke Yi, Jiajin Li, Jufeng Ye

{"title":"The diagnostic value of CYFRA 21-1 in oral squamous cell carcinoma: a meta-analysis.","authors":"Yuting Liang, Zhenke Yi, Jiajin Li, Jufeng Ye","doi":"10.1080/14737140.2024.2405225","DOIUrl":"10.1080/14737140.2024.2405225","url":null,"abstract":"Background: Previous studies have revealed the importance of CYFRA 21-1 in the diagnosis of oral squamous cell cancer (OSCC). However, the results are inconsistent. This meta-analysis is to evaluate CYFRA 21-1's efficacy in distinguishing OSCC.Methods: Systematic searches of Web of Science, PubMed, and CNKI (1996-2024) were conducted following the Preferred Reporting ltems for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.Results: Analysis of 693 patients and 548 controls yielded combined sensitivity (SEN) of 0.71 (95% CI: 0.68, 0.75), specificity (SPE) of 0.88 (95% CI: 0.85, 0.90), and area under the curve (AUC) of 0.927. Subgroup analysis showed higher SEN (0.88), SPE (0.93), and AUC (0.962) in saliva versus serum. Enzyme-linked immunosorbent assay (ELISA) demonstrated superior performance over electrochemiluminescent immunoassay (ECLIA) (AUC: 0.968 vs. 0.868).Conclusion: CYFRA 21-1 is effective in OSCC diagnosis, with ELISA showing better sensitivity. Saliva emerges as a promising diagnostic medium compared to serum.Registration: PROSPERO CRD42024566835.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1161-1168"},"PeriodicalIF":2.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimising CAR T therapy for the treatment of solid tumors. 优化治疗实体瘤的 CAR T 疗法。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-10-28 DOI: 10.1080/14737140.2024.2421194

Norhan Mobark, Caroline Malai Hull, John Maher

{"title":"Optimising CAR T therapy for the treatment of solid tumors.","authors":"Norhan Mobark, Caroline Malai Hull, John Maher","doi":"10.1080/14737140.2024.2421194","DOIUrl":"https://doi.org/10.1080/14737140.2024.2421194","url":null,"abstract":"Introduction: Adoptive immunotherapy using chimeric antigen receptor (CAR)-engineered T cells has proven transformative in the management of B cell and plasma cel derived malignancies. However, solid tumors have largely proven to be resistant to this therapeutic modality. Challenges include the paucity of safe target antigens, heterogeneity of target expression within the tumor, difficulty in delivery of CAR T cells to the site of disease, poor penetration within solid tumor deposits and inability to circumvent the array of immunosuppressive and biophysical barriers imposed by the solid tumor microenvironment.Areas covered: Literature was reviewed on the PubMed database, excluding occasional papers which were not available as open access publications or through other means.Expert opinion: Here, we have surveyed the large body of technological advances that have been made in the quest to bridge the gap toward successful deployment of CAR T cells for the treatment of solid tumors. These encompass the development of more sophisticated targeting strategies to engage solid tumor cells safely and comprehensively, improved drug delivery solutions, design of novel CAR architectures that achieve improved functional persistence and which resist physical, chemical and biological hurdles present in tumor deposits. Prospects for combination therapies that incorporate CAR T cells are also considered.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-17"},"PeriodicalIF":2.9,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The efficacy of Veliparib in combination with chemotherapy in the treatment of lung cancer: systematic review and meta-analysis. 维利帕尼联合化疗治疗肺癌的疗效：系统综述和荟萃分析。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2024-10-20 DOI: 10.1080/14737140.2024.2417770

Muataz Kashbour, Abdulhameed Alhadeethi, Sara Awwad, Mazen Yassin, Ahmed Amin, Mohamed Abed, Abubaker Abdelmalik, Yasmeen Jamal Alabdallat

{"title":"The efficacy of Veliparib in combination with chemotherapy in the treatment of lung cancer: systematic review and meta-analysis.","authors":"Muataz Kashbour, Abdulhameed Alhadeethi, Sara Awwad, Mazen Yassin, Ahmed Amin, Mohamed Abed, Abubaker Abdelmalik, Yasmeen Jamal Alabdallat","doi":"10.1080/14737140.2024.2417770","DOIUrl":"https://doi.org/10.1080/14737140.2024.2417770","url":null,"abstract":"Objective: This meta-analysis aims to examine the effectiveness of veliparib, a poly ADP-ribose polymerase inhibitor, in combination with chemotherapy in treating bronchogenic carcinoma.Methods: PubMed, Cochrane, Scopus, and Web of Science were searched for eligible randomized controlled trials comparing veliparib plus chemotherapy to standard chemotherapy in adult lung cancer patients, until July 2023. The main outcomes were overall survival (OS) and progression-free survival (PFS).Results: This meta-analysis included six studies encompassing 2,136 patients. Veliparib has a slight OS improvement over placebo, HR = 0.91, 95% CI [0.83 to 1.0], p = 0.05. Veliparib offers more OS benefit in the subpopulation of non-small cell lung cancer (NSCLC) than small-cell lung cancer (SCLC), HR = 0.89, 95% CI [0.81,0.99], p = 0.03 and HR = 1.00, 95% CI [0.79, 1.28], p = 0.97, respectively. There was no significant PFS benefit between the two groups, HR = 0.92, 95% CI [0.81-1.01], p = 0.08).Conclusion: Veliparib has a marginal inclination for overall survival improvement, more so in NSCLC, with an acceptable safety profile. Our results merit the pursuit of better-powered trials to support further the extent of veliparib's effectiveness in lung cancer patients.Registration: PROSPERO (CRD42023453705).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.9,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0